SCHEMBL12892076

SCHEMBL12892076

Cc1ccc(-c2nn(-c3ccccc3)cc2/C=C2\SC(=S)NC2=O)o1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 7/20 0.61
KMT2A Q03164 7/20 0.61
POLB P06746 5/20 0.61
ALDH1A1 P00352 5/20 0.61
KDM4E B2RXH2 3/20 0.61
RECQL P46063 3/20 0.61
SMN1; SMN2 Q16637 2/20 0.61
RAB9A P51151 2/20 0.61
THRB P10828 1/20 0.61
PKM P14618 1/20 0.61
BLM P54132 1/20 0.59
MAPT P10636 4/20 0.59
NPSR1 Q6W5P4 3/20 0.59
MAPK1 P28482 2/20 0.59
LMNA P02545 2/20 0.59
HPGD P15428 2/20 0.59
HTT P42858 2/20 0.59
MCL1 Q07820 1/20 0.59
SAE1 Q9UBE0 1/20 0.59
UBA2 Q9UBT2 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14133570 0.84 MAPT (0.66) MEN1KMT2APOLBKDM4ESMN1; SMN2
SCHEMBL3635890 0.77 ALDH1A1 (1.00) MEN1KMT2APOLBALDH1A1KDM4E
SCHEMBL14133357 0.74 MEN1 (0.60) MEN1KMT2APOLBSMN1; SMN2MAPT
SCHEMBL14132635 0.74 PTGES (0.67) MEN1KMT2APOLBALDH1A1KDM4E
SCHEMBL14133409 0.74 DUSP3 (0.67) MEN1KMT2APOLBSMN1; SMN2MAPT
SCHEMBL13345210 0.73 PLK1 (0.65) MEN1KMT2APOLBSMN1; SMN2PKM
SCHEMBL23036942 0.72 MTOR (0.59) ALDH1A1KDM4EMAPTMAPK1MTOR
SCHEMBL14132600 0.71 MAPT (0.60) MEN1KMT2APOLBALDH1A1KDM4E
SCHEMBL14132901 0.71 PLK1 (0.62) MEN1KMT2APOLBSMN1; SMN2PKM
SCHEMBL23036927 0.70 MTOR (1.00) MEN1KMT2APOLBALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7879893-B2 Zinc binding ligand; sustained release of insulin NOVO NORDISK A/S (DK) 2011-02-01 US disclosed
US-7879893-B2 Zinc binding ligand; sustained release of insulin NOVO NORDISK A/S (DK) 2011-02-01 US disclosed
US-20090123563-A1 Pharmaceutical Preparations Comprising Insulin, Zinc Ions and Zinc-Binding Ligand NOVO NORDISK A/S (DK) 2009-05-14 US disclosed
US-20090123563-A1 Pharmaceutical Preparations Comprising Insulin, Zinc Ions and Zinc-Binding Ligand NOVO NORDISK A/S (DK) 2009-05-14 US disclosed
EP-1429763-B1 NOVEL LIGANDS FOR THE HisB10 Zn2+ SITES OF THE R-STATE INSULIN HEXAMER NOVO NORDISK AS (DK) 2007-05-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090123563-A1 Pharmaceutical Preparations Comprising Insulin, Zinc Ions and Zinc-Binding Ligand IAPP, IRS1, HBB MEN1 912/4885KMT2A 4327/4885POLB 2360/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.